Robert A. Lenz - 03 Jun 2026 Form 4 Insider Report for LB PHARMACEUTICALS INC (LBRX)

Reporting relationship: Director
Issuer ticker: LBRX
Reported as of: 03 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 05 Jun 2026, 17:26:45 UTC
Prior SEC filing: 18 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Marc Panoff, Attorney-in-Fact

Key filing fact

Robert A. Lenz filed Form 4 for LB PHARMACEUTICALS INC (LBRX) on 05 Jun 2026.

Key facts

This page summarizes Robert A. Lenz's Form 4 filing for LB PHARMACEUTICALS INC (LBRX).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 05 Jun 2026, 17:26.

Change

Previous filing in this sequence was filed on 18 Mar 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001992908 Primary reporting owner

Lenz Robert A.

Relationship: Director
Address: C/O LB PHARMACEUTICALS INC, ONE PENNSYLVANIA PLAZA, SUITE 1025, NEW YORK
Signature: /s/ Marc Panoff, Attorney-in-Fact
Signature date: 05 Jun 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

LBRX transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +12,500
Change %
Price: $0.000000^*
Shares after: 12,500
Date: 03 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 12,500
Exercise price: $27.95
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Includes an option award for 2,500 shares pursuant to the Issuer's non-employee director compensation policy which represents a prorated annual grant for the previous year.

Footnote F2

100% of the shares underlying the option vest on the earlier of (i) June 3, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through such vesting date.